Irbesartan Viatris

Irbesartan, the active ingredient in Irbesartan Viatris, is an angiotensin II receptor blocker (ARB) presented as tablets for oral use. It helps lower elevated blood pressure and is indicated for hypertension, diabetic nephropathy, and heart failure in adult patients.

GNH USA supplies Irbesartan Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, meeting EU regulatory standards and ensuring consistent potency and safety.

Irbesartan acts on the renin‑angiotensin‑aldosterone system to manage several cardiovascular and renal conditions.

Hypertension: reduces systolic and diastolic blood pressure, lowering cardiovascular risk. Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. Heart failure: improves symptoms and reduces hospitalisation in patients with chronic heart failure.

Irbesartan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness. - Nausea: occasional stomach upset.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue or throat requiring emergency care. - Acute renal failure: sudden decline in kidney function, indicated by rising creatinine. - Severe hyperkalemia: markedly elevated potassium that can affect heart rhythm.

When prescribing Irbesartan, clinicians should consider several safety measures. - Monitor blood pressure: adjust therapy based on readings. - Assess renal function: check serum creatinine and eGFR before and during treatment. - Check electrolytes: especially potassium levels periodically. - Avoid use in pregnancy: drug is contraindicated due to fetal risk. - Use caution in hepatic impairment: dose may need adjustment. - Store at room temperature: keep in original packaging, protect from moisture and light.

Irbesartan can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concomitant use with aliskiren in patients with diabetes: increased risk of renal impairment. - Dual therapy with ACE inhibitors or other ARBs: may cause excessive potassium rise and renal dysfunction. - Potassium‑sparing diuretics (e.g., spironolactone): risk of severe hyperkalemia.

Moderate Interactions (Monitor Closely): - Lithium: may increase lithium levels, requiring serum monitoring. - NSAIDs: can reduce antihypertensive effect and affect renal function. - Cyclosporine or tacrolimus: may increase serum irbesartan concentrations.